Takeda recently broke ground on a new 15,000 square foot manufacturing facility, as well as a complete renovation of an existing 14,000 square foot manufacturing space in Thousand Oaks, CA. The $126 million investment increases the site’s capacity to manufacture additional products for the rare disease community. This is also reflected in the site’s motto “Every Vial Has a Name.”
 
The new facility will utilize automation, robotics and digitization to significantly minimize the potential for human errors. Virtual reality training systems will be integrated to educate staff prior to commercial production, providing employees with hands-on experience in a safe-to-fail environment. These features will enable the facility’s manufacturing to be a quicker, more reliable and repeatable process that generates high quality and safe products.
 
“We are grateful for the contributions the Thousand Oaks team and the Global Manufacturing and Supply organization continue to make to ensure we consistently deliver the treatments that people with rare diseases depend on to live their lives,” said Cheryl Schwartz, senior vice president and business unit lead, US rare disease business unit, Takeda. “The added capability and expertise of this expansion further enables Takeda’s support of the rare disease community.”
 
In addition to the construction of the new manufacturing facility, the Thousand Oaks site is helping to deliver on the company’s commitment to reduce its greenhouse gas emissions by investing in new technologies that utilize renewable electricity. Measures are in place to reduce water consumption and identify water risks to ensure undisrupted supply. Takeda achieved carbon neutrality for its entire supply chain in 2020, and the site aims to reduce 40 percent of its greenhouse gas emissions by 2025. A major solar project slated to start in the second half of 2021 will meet 44 percent of the site`s 2025 greenhouse emission goals.